Clinical Trial: Inhaled DMT for Major Depressive Disorder

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562191) titled 'Inhaled DMT for Major Depressive Disorder' on March 27.

Brief Summary: This Phase 2b, randomized, double-blind, active-controlled clinical trial will evaluate the efficacy and safety of inhaled N,N-dimethyltryptamine (DMT) in adults with Major Depressive Disorder (MDD).

The study will test whether inhaled DMT can rapidly reduce depressive symptoms and suicide risk compared with a low-dose active comparator. A total of 140 participants will be randomized 1:1 to receive either 15 mg followed 1 hour later by 60 mg of inhaled DMT, or 1 mg followed 1 hour later by 4 mg of inhaled DMT.

Participants who do not achieve remission at Day 7 wi...